MedTrace Logo

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

NCT00516724 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2025-04-11

No results posted yet for this study

Summary

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.

Conditions

Interventions

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

DRUG

Carboplatin

intravenous injection

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

Oral

DRUG

Paclitaxel

Intravenous injection

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

Oral

DRUG

Paclitaxel + Carboplatin

Intravenous injection

Sponsors & Collaborators

Principal Investigators

  • Jane Robertson, BSc, MBCHB, MD · AstraZeneca

  • Dr Johann de Bono, MD · Cancer Research UK, The Institute of Cancer Research, London, UK

  • Prof Jan HM Schellens · The Netherlands Cancer Institute, Amsterdam, The Netherlands

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-22
Primary Completion
2013-01-04
Completion
2024-04-11

Countries

  • Belgium
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00516724 on ClinicalTrials.gov